Genetic modification of dividing cells using episomally maintained S/MAR DNA vectors

Molecular Therapy Nucleic Acids

Volumn 2, Issue AUG, 2013, Pages e115-

  Wong, Suet Ping ^a   Harbottle, Richard Paul ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRONE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CLONAL VARIATION; COLONY FORMATION; CONTROLLED STUDY; DNA MODIFICATION; DNA VECTOR; EMBRYONIC STEM CELL; EPISOME; GENE EXPRESSION; GLYCOLYSIS; GROWTH RATE; IN VITRO STUDY; IN VIVO STUDY; LIPID OXIDATION; MATRIX ATTACHMENT REGION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

EID: 84884266617     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.40     Document Type: Article

References (38)

1. Pannell, D and Ellis, J (2001). Silencing of gene expression: implications for design of retrovirus vectors. Rev Med Virol 11: 205-217. (Pubitemid 32737644)
2. Nagel, J, Gross, B, Meggendorfer, M, Preiss, C, Grez, M, Brack-Werner, R et al. (2012). Stably integrated and expressed retroviral sequences can influence nuclear location and chromatin condensation of the integration locus. Chromosoma 121: 353-367.
3. Argyros, O, Wong, SP, Gowers, K and Harbottle, RP (2012). Genetic modification of cancer cells using non-viral, episomal S/MAR vectors for in vivo tumour modelling. PLoS ONE 7: e47920.
4. Argyros, O, Wong, SP, Fedonidis, C, Tolmachov, O, Waddington, SN, Howe, SJ et al. (2011). Development of S/MAR minicircles for enhanced and persistent transgene expression in the mouse liver. J Mol Med 89: 515-529.
5. Jenke, AC, Stehle, IM, Herrmann, F, Eisenberger, T, Baiker, A, Bode, J et al. (2004). Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc Natl Acad Sci USA 101: 11322-11327. (Pubitemid 39038345)
6. Schmidt, LS, Nickerson, ML, Warren, MB, Glenn, GM, Toro, JR, Merino, MJ et al. (2005). Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet 76: 1023-1033. (Pubitemid 40705436)
7. Nickerson, ML, Warren, MB, Toro, JR, Matrosova, V, Glenn, G, Turner, ML et al. (2002). Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2: 157-164. (Pubitemid 41039116)
8. Yang, Y, Padilla-Nash, HM, Vira, MA, Abu-Asab, MS, Val, D, Worrell, R et al. (2008). The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dubé gene pathway. Cancer Genet Cytogenet 180: 100-109.
9. Petersson, F, Gatalica, Z, Grossmann, P, Perez Montiel, MD, Alvarado Cabrero, I, Bulimbasic, S et al. (2010). Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch 456: 355-365.
10. Hong, SB, Oh, H, Valera, VA, Baba, M, Schmidt, LS and Linehan, WM (2010). Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS ONE 5: e15793.
11. Hong, SB, Oh, H, Valera, VA, Stull, J, Ngo, DT, Baba, M et al. (2010). Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-® signaling. Mol Cancer 9: 160.
12. Baba, M, Hong, SB, Sharma, N, Warren, MB, Nickerson, ML, Iwamatsu, A et al. (2006). Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci USA 103: 15552-15557. (Pubitemid 44625630)
13. Hasumi, H, Baba, M, Hong, SB, Hasumi, Y, Huang, Y, Yao, M et al. (2008). Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 415: 60-67.
14. Hartman, TR, Nicolas, E, Klein-Szanto, A, Al-Saleem, T, Cash, TP, Simon, MC et al. (2009). The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. Oncogene 28: 1594-1604.
15. Hudon, V, Sabourin, S, Dydensborg, AB, Kottis, V, Ghazi, A, Paquet, M et al. (2010). Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin. J Med Genet 47: 182-189.
16. Cash, TP, Gruber, JJ, Hartman, TR, Henske, EP and Simon, MC (2011). Loss of the Birt-Hogg-Dubé tumor suppressor results in apoptotic resistance due to aberrant TGFßmediated transcription. Oncogene 30: 2534-2546.
17. Medvetz, DA, Khabibullin, D, Hariharan, V, Ongusaha, PP, Goncharova, EA, Schlechter, T et al. (2012). Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion. PLoS ONE 7: e47842.
18. Galbete, JL, Buceta, M and Mermod, N (2009). MAR elements regulate the probability of epigenetic switching between active and inactive gene expression. Mol Biosyst 5: 143-150.
19. Heikkinen, PT, Nummela, M, Jokilehto, T, Grenman, R, Kähäri, VM and Jaakkola, PM (2010). Hypoxic conversion of SMAD7 function from an inhibitor into a promoter of cell invasion. Cancer Res 70: 5984-5993.
20. Siegel, PM and Massagué, J (2003). Cytostatic and apoptotic actions of TGF-® in homeostasis and cancer. Nat Rev Cancer 3: 807-821.
21. Nathan, CO, Amirghahari, N, Abreo, F, Rong, X, Caldito, G, Jones, ML et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway (2004). Clin Cancer Res 10: 5820-5827.
22. Preston, RS, Philp, A, Claessens, T, Gijezen, L, Dydensborg, AB, Dunlop, EA et al. (2011). Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility. Oncogene 30: 1159-1173.
23. Vinci, M, Gowan, S, Boxall, F, Patterson, L, Zimmermann, M, Court, W et al. (2012). Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 10: 29.
24. Jenke, BH, Fetzer, CP, Stehle, IM, Jönsson, F, Fackelmayer, FO, Conradt, H et al. (2002). An episomally replicating vector binds to the nuclear matrix protein SAF-A in vivo. EMBO Rep 3: 349-354. (Pubitemid 34467605)
25. Argyros, O, Wong, SP, Niceta, M, Waddington, SN, Howe, SJ, Coutelle, C et al. (2008). Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Ther 15: 1593-1605.
26. Wong, SP, Argyros, O, Coutelle, C and Harbottle, RP (2011). Non-viral S/MAR vectors replicate episomally in vivo when provided with a selective advantage. Gene Ther 18: 82-87.
27. Lufino, MM, Manservigi, R and Wade-Martins, R (2007). An S/MAR-based infectious episomal genomic DNA expression vector provides long-term regulated functional complementation of LDLR deficiency. Nucleic Acids Res 35: e98.
28. Jenke, AC, Eisenberger, T, Baiker, A, Stehle, IM, Wirth, S and Lipps, HJ (2005). The nonviral episomal replicating vector pEPI-1 allows long-term inhibition of bcr-abl expression by shRNA. Hum Gene Ther 16: 533-539. (Pubitemid 40647151)
29. Jenke, AC, Scinteie, MF, Stehle, IM and Lipps, HJ (2004). Expression of a transgene encoded on a non-viral episomal vector is not subject to epigenetic silencing by cytosine methylation. Mol Biol Rep 31: 85-90. (Pubitemid 38881797)
30. Argyros, O, Wong, SP and Harbottle, RP (2011). Non-viral episomal modification of cells using S/MAR elements. Expert Opin Biol Ther 11: 1177-1191.
31. Han, SU, Kim, HT, Seong, DH, Kim, YS, Park, YS, Bang, YJ et al. (2004). Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene 23: 1333-1341. (Pubitemid 38406829)
32. Takagi, Y, Kohmura, H, Futamura, M, Kida, H, Tanemura, H, Shimokawa, K et al. (1996). Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology 111: 1369-1372. (Pubitemid 26362263)
33. Grünert, S, Jechlinger, M and Beug, H (2003). Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4: 657-665. (Pubitemid 36934968)
34. Do, TV, Kubba, LA, Du, H, Sturgis, CD and Woodruff, TK. Transforming growth factor-®1, transforming growth factor-®2, and transforming growth factor-®3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition (2008). Mol Cancer Res 6: 695-705.
35. Javelaud, D, Mohammad, KS, McKenna, CR, Fournier, P, Luciani, F, Niewolna, M et al. (2007). Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 67: 2317-2324. (Pubitemid 46424252)
36. Higgins, JP, Shinghal, R, Gill, H, Reese, JH, Terris, M, Cohen, RJ et al. (2003). Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 162: 925-932. (Pubitemid 36237499)
37. Laviolette, L, Wilson, J, Koller, J, Zimmer, M and Iliopoulos, O (2012). Abstract 2171: Human FLCN delays cell cycle progression through late S and G2/M-phases: Effect of phosphorylation and tumor-associated mutations. Can Res 72.
38. Baba, M, Keller, JR, Sun, HW, Resch, W, Kuchen, S, Suh, HC et al. (2012). The folliculin- FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development. Blood 120: 1254-1261